China Oncology ›› 2023, Vol. 33 ›› Issue (4): 397-402.doi: 10.19401/j.cnki.1007-3639.2023.04.010
• Review • Previous Articles Next Articles
LIU Jialin(), ZHANG Xianyu, PANG Da()
Received:
2022-06-20
Revised:
2022-10-17
Online:
2023-04-30
Published:
2023-05-15
Contact:
PANG Da
CLC Number:
LIU Jialin, ZHANG Xianyu, PANG Da. Research progress of adaptive therapy strategy based on Darwinian dynamics in tumor therapy[J]. China Oncology, 2023, 33(4): 397-402.
[1] |
CHEN Y L, CHANG M C, CHENG W F. Metronomic chemotherapy and immunotherapy in cancer treatment[J]. Cancer Lett, 2017, 400: 282-292.
doi: 10.1016/j.canlet.2017.01.040 |
[2] |
GATENBY R A, BROWN J S. Integrating evolutionary dynamics into cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(11): 675-686.
doi: 10.1038/s41571-020-0411-1 |
[3] |
MCGRANAHAN N, SWANTON C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution[J]. Cancer Cell, 2015, 27(1): 15-26.
doi: 10.1016/j.ccell.2014.12.001 pmid: 25584892 |
[4] |
JOHNSON D B, MENZIES A M, ZIMMER L, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms[J]. Eur J Cancer, 2015, 51(18): 2792-2799.
doi: 10.1016/j.ejca.2015.08.022 pmid: 26608120 |
[5] | ENRIQUEZ-NAVAS P M, WOJTKOWIAK J W, GATENBY R A. Application of evolutionary principles to cancer therapy[J]. Cancer Res, 2015, 75(22): 4675-4680. |
[6] |
SHAFFER S M, DUNAGIN M C, TORBORG S R, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance[J]. Nature, 2017, 546(7658): 431-435.
doi: 10.1038/nature22794 |
[7] |
SAUNDERS N A, SIMPSON F, THOMPSON E W, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives[J]. EMBO Mol Med, 2012, 4(8): 675-684.
doi: 10.1002/emmm.201101131 pmid: 22733553 |
[8] |
GATENBY R A, SILVA A S, GILLIES R J, et al. Adaptive therapy[J]. Cancer Res, 2009, 69(11): 4894-4903.
doi: 10.1158/0008-5472.CAN-08-3658 pmid: 19487300 |
[9] |
SIRAVEGNA G, MUSSOLIN B, BUSCARINO M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients[J]. Nat Med, 2015, 21(7): 827.
doi: 10.1038/nm0715-827b pmid: 26151329 |
[10] |
SCHREUER M, JANSEN Y, PLANKEN S, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial[J]. Lancet Oncol, 2017, 18(4): 464-472.
doi: 10.1016/S1470-2045(17)30171-7 |
[11] |
SMALLEY I, KIM E, LI J N, et al. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma[J]. EBioMedicine, 2019, 48: 178-190.
doi: S2352-3964(19)30627-9 pmid: 31594749 |
[12] |
ZHANG J S, CUNNINGHAM J J, BROWN J S, et al. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer[J]. Nat Commun, 2017, 8(1): 1816.
doi: 10.1038/s41467-017-01968-5 pmid: 29180633 |
[13] | ENRIQUEZ-NAVAS P M, KAM Y, DAS T, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer[J]. Sci Transl Med, 2016, 8(327): 327ra24. |
[14] |
SILVA A S, KAM Y, KHIN Z P, et al. Evolutionary approaches to prolong progression-free survival in breast cancer[J]. Cancer Res, 2012, 72(24): 6362-6370.
doi: 10.1158/0008-5472.CAN-12-2235 pmid: 23066036 |
[15] |
BACEVIC K, NOBLE R, SOFFAR A, et al. Spatial competition constrains resistance to targeted cancer therapy[J]. Nat Commun, 2017, 8(1): 1995.
doi: 10.1038/s41467-017-01516-1 pmid: 29222471 |
[16] |
STROBL M A R, WEST J, VIOSSAT Y, et al. Turnover modulates the need for a cost of resistance in adaptive therapy[J]. Cancer Res, 2021, 81(4): 1135-1147.
doi: 10.1158/0008-5472.CAN-20-0806 pmid: 33172930 |
[17] |
VIOSSAT Y, NOBLE R. A theoretical analysis of tumour containment[J]. Nat Ecol Evol, 2021, 5(6): 826-835.
doi: 10.1038/s41559-021-01428-w pmid: 33846605 |
[18] |
CUNNINGHAM J, THUIJSMAN F, PEETERS R, et al. Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer[J]. PLoS One, 2020, 15(12): e0243386.
doi: 10.1371/journal.pone.0243386 |
[19] |
BELKHIR S, THOMAS F, ROCHE B. Darwinian approaches for cancer treatment: benefits of mathematical modeling[J]. Cancers, 2021, 13(17): 4448.
doi: 10.3390/cancers13174448 |
[20] |
KIMKO H, PINHEIRO J. Model-based clinical drug development in the past, present and future: a commentary[J]. Br J Clin Pharmacol, 2015, 79(1): 108-116.
doi: 10.1111/bcp.12341 pmid: 24527997 |
[21] |
YIN A Y, VAN HASSELT J G C, GUCHELAAR H J, et al. Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance[J]. Sci Rep, 2022, 12(1): 4206.
doi: 10.1038/s41598-022-08012-7 pmid: 35273301 |
[22] |
JI J T, WU H, FENG X B, et al. Dynamics of acquired resistance to nivolumab therapies varies from administration strategies[J]. Clin Ther, 2021, 43(12): 2088-2103.
doi: 10.1016/j.clinthera.2021.10.004 pmid: 34782163 |
[23] |
WEST J B, DINH M N, BROWN J S, et al. Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy[J]. Clin Cancer Res, 2019, 25(14): 4413-4421.
doi: 10.1158/1078-0432.CCR-19-0006 pmid: 30992299 |
[24] |
MA Y, NEWTON P K. Role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules[J]. Phys Rev E, 2021, 103(): 032408.
doi: 10.1103/PhysRevE.103.032408 |
[25] |
KIM E, BROWN J S, EROGLU Z, et al. Adaptive therapy for metastatic melanoma: predictions from patient calibrated mathematical models[J]. Cancers (Basel), 2021, 13(4): 823.
doi: 10.3390/cancers13040823 |
[26] |
WANG Z H, BUTNER J D, KERKETTA R, et al. Simulating cancer growth with multiscale agent-based modeling[J]. Semin Cancer Biol, 2015, 30: 70-78.
doi: 10.1016/j.semcancer.2014.04.001 pmid: 24793698 |
[27] |
DEISBOECK T S, WANG Z, MACKLIN P, et al. Multiscale cancer modeling[J]. Annu Rev Biomed Eng, 2011, 13: 127-155.
doi: 10.1146/annurev-bioeng-071910-124729 pmid: 21529163 |
[28] | JOHNSON D, MCKEEVER S, STAMATAKOS G, et al. Dealing with diversity in computational cancer modeling[J]. Cancer Inform, 2013, 12: 115-124. |
[29] |
REJNIAK K A, ANDERSON A R A. Hybrid models of tumor growth[J]. Wiley Interdiscip Rev Syst Biol Med, 2011, 3(1): 115-125.
doi: 10.1002/wsbm.v3.1 |
[30] |
CHISHOLM R H, LORENZI T, CLAIRAMBAULT J. Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation[J]. Biochim Biophys Acta, 2016, 1860(11 Pt B): 2627-2645.
doi: 10.1016/j.bbagen.2016.06.009 pmid: 27339473 |
[31] |
YOU L, BROWN J S, THUIJSMAN F, et al. Spatial vs non-spatial eco-evolutionary dynamics in a tumor growth model[J]. J Theor Biol, 2017, 435: 78-97.
doi: 10.1016/j.jtbi.2017.08.022 |
[32] | STROBL M A R, GALLAHER J, WEST J, et al. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition[J]. Commun Med (Lond), 2022, 2: 46. |
[33] |
FU X, ZHAO Y, LOPEZ J I, et al. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx renal study[J]. Nat Ecol Evol, 2022, 6(1): 88-102.
doi: 10.1038/s41559-021-01586-x |
[34] |
GALLAHER J A, ENRIQUEZ-NAVAS P M, LUDDY K A, et al. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies[J]. Cancer Res, 2018, 78(8): 2127-2139.
doi: 10.1158/0008-5472.CAN-17-2649 pmid: 29382708 |
[35] |
STOREY K M, JACKSON T L. An agent-based model of combination oncolytic viral therapy and anti-PD-1 immunotherapy reveals the importance of spatial location when treating glioblastoma[J]. Cancers (Basel), 2021, 13(21): 5314.
doi: 10.3390/cancers13215314 |
[36] |
PIN C, COLLINS T, GIBBS M, et al. Systems modeling to quantify safety risks in early drug development: using bifurcation analysis and agent-based modeling as examples[J]. AAPS J, 2021, 23(4): 77.
doi: 10.1208/s12248-021-00580-2 pmid: 34018069 |
[37] |
ROJAS-DOMÍNGUEZ A, ARROYO-DUARTE R, RINCÓN-VIEYRA F, et al. Modeling cancer immunoediting in tumor microenvironment with system characterization through the Ising-model Hamiltonian[J]. BMC Bioinformatics, 2022, 23(1): 200.
doi: 10.1186/s12859-022-04731-w |
[38] |
GATENBY R A, BROWN J S. The evolution and ecology of resistance in cancer therapy[J]. Cold Spring Harb Perspect Med, 2020, 10(11): a040972.
doi: 10.1101/cshperspect.a040972 |
[39] |
MALEY C C, REID B J, FORREST S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(8): 1375-1384.
doi: 10.1158/1055-9965.1375.13.8 |
[40] | SCHWEIZER M T, ANTONARAKIS E S, WANG H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study[J]. Sci Transl Med, 2015, 7(269): 269ra2. |
[41] |
SENA L A, WANG H, LIM SCM S J, et al. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy[J]. Eur J Cancer, 2021, 144: 302-309.
doi: 10.1016/j.ejca.2020.11.043 pmid: 33383350 |
[42] |
GATENBY R A, BROWN J, VINCENT T. Lessons from applied ecology: cancer control using an evolutionary double bind[J]. Cancer Res, 2009, 69(19): 7499-7502.
doi: 10.1158/0008-5472.CAN-09-1354 pmid: 19752088 |
[43] |
ANTONIA S J, MIRZA N, FRICKE I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer[J]. Clin Cancer Res, 2006, 12(3): 878-887.
doi: 10.1158/1078-0432.CCR-05-2013 |
[44] |
STANKOVÁ K, BROWN J S, DALTON W S, et al. Optimizing cancer treatment using game theory: a review[J]. JAMA Oncol, 2019, 5(1): 96-103.
doi: 10.1001/jamaoncol.2018.3395 pmid: 30098166 |
[1] | CHEN Yingyao, CHU Xiangling, YU Xin, SU Chunxia. Advances in models predicting efficacy of immune checkpoint inhibitors [J]. China Oncology, 2023, 33(1): 61-70. |
[2] | XUE Ying, MAO Yunyu, XU Jianqing. Progress in construction of hypoxia-sensitive CAR-T cell for solid tumor therapy [J]. China Oncology, 2023, 33(1): 71-77. |
[3] | GUO Zhaoyang, HU Jingzhou. Research progress and prospect of Siglec in innate immune cells in tumor [J]. China Oncology, 2022, 32(12): 1235-1241. |
[4] | Society of Onco-endocrinology of Chinese Anti-Cancer Association. Expert consensus on metformin adjuvant therapy in malignant tumor patients with diabetes mellitus type 2 (2022 edition) [J]. China Oncology, 2022, 32(11): 1121-1132. |
[5] | CHEN Yifan, SHEN Yihui, CHENG Leilei, LIN Jinyi, ZHANG Hui, WANG Xuejun, XU Yuchen, ZHANG Jian, GE Junbo. Different preventive effects of four cardioprotective agents on mice with adriamycin-induced cardiotoxicity [J]. China Oncology, 2022, 32(10): 936-947. |
[6] | LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie. Updates on medical treatment for neuroendocrine neoplasm [J]. China Oncology, 2022, 32(9): 757-764. |
[7] | HU Xichun, HU Zhihuang, WANG Biyun, WANG Jialei, TAO Rong, ZHANG Jian, GUO Weijian, CHEN Jie, LUO Zhiguo, LI Ting, HUANG Mingzhu, QIU Lixin, SANG Youzhou. COVID-19 and systemic anti-cancer therapy [J]. China Oncology, 2022, 32(6): 499-511. |
[8] | LI Fan, ZHANG Qinxing, TONG Xiangwen, TIAN Gaohui, GU Lixing, XU Yao. A study on influence of different signal peptides on anti-tumor effect of chimeric antigen receptor (CAR) T cells [J]. China Oncology, 2022, 32(2): 142-151. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd